CCMB Researchers Discover Compounds to Combat Candida Infections
New compounds identified by CCMB prevent Candida albicans from transforming into its pathogenic form, potentially enhancing treatment options.
Two compounds identified that inhibit Candida albicans' filamentous transformation.
Research shows potential to improve existing antifungal treatments.
Further studies are needed to assess safety and efficacy in humans.
Scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad have made a significant breakthrough by identifying two compounds that prevent the fungus Candida albicans from transforming into its filamentous form, which is associated with infections. This transformation complicates the immune response, making infections harder to control. The lead compound has shown promise in improving survival rates in mice suffering from systemic Candida infections, marking an important step towards developing new antifungal treatments.
The study, conducted by Dr. Sriram Varahan’s laboratory and published in ACS Infectious Diseases, investigates the potential of modifying fungal behavior to complement existing antifungal therapies. Candida albicans is a common fungus found on human skin, but it can lead to serious infections when it enters the bloodstream or internal organs. The research highlights the importance of understanding the metabolic pathways that regulate the fungus's shape, particularly glycolysis, which is crucial for its energy production and morphological changes.
In their experiments, the researchers screened a library of small molecules targeting glycolysis and discovered two compounds that effectively inhibited the formation of filaments while allowing the fungus to grow in its rounded form. Additionally, the study identified pyruvate kinase, an enzyme involved in glycolysis, as a key target for controlling the morphological changes of the fungus. One of the compounds also demonstrated the ability to reduce biofilm formation, which is known to protect the fungus from antifungal treatments, thereby increasing its susceptibility to drugs like fluconazole and amphotericin B.
The implications of this research are significant, especially in light of the increasing prevalence of fungal pathogens and the limited number of antifungal drugs available. The emergence of drug-resistant strains poses a serious threat to treatment options, making the development of new strategies crucial. The findings suggest that targeting the metabolic regulation of fungi could enhance the effectiveness of existing therapies and address the growing concern of resistance.
Despite the promising results, further research is necessary to fully understand how these compounds function, optimize their properties, and evaluate their therapeutic potential in humans. Dr. Varahan emphasized that while the study provides a foundation for future antifungal drug development, the compounds are not yet approved for clinical use and require extensive testing to confirm their safety and efficacy.




